BridgeBio Pharma shares jumped 9.3% on strong Q4 revenue growth despite a loss, driven by genetic disease and cancer drug progress.

BridgeBio Pharma (BBIO) shares rose on Tuesday, gaining 9.3% to $71.76, after reporting Q4 revenue of $154.18 million—up 2,521% year-over-year and exceeding estimates—despite a $1.00 per share loss, missing expectations by $0.25. Analysts maintain a "Moderate Buy" consensus rating with an average 1-year price target of $82.50, while JPMorgan raised its target to $94.00 and HC Wainwright upgraded to "Buy" with a $100.00 target. The company, based in Palo Alto, focuses on genetic disease and cancer therapies, with multiple pipeline candidates advancing. Insider selling totaled $16.1 million in the past quarter, reducing ownership to 18.20%, while institutional holdings remain at 99.85%.